Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study
| Status: | Completed |
|---|---|
| Conditions: | Fibromyalgia, Pain |
| Therapuetic Areas: | Musculoskeletal, Rheumatology |
| Healthy: | No |
| Age Range: | 22 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | August 2013 |
| End Date: | May 2014 |
An Open Label Extension Trial for Patients With Fibromyalgia Who Complete Study NPT-201 (NCT01825954) and Who Experience Inadequate Pain Reduction
The purpose of this open label study is to provide up to 24 active treatments of noninvasive
cortical electrostimulation therapy only to those fibromyalgia patients who experienced
inadequate pain reduction in a sham controlled double blinded lead in study, NPT-201
(NCT01825954). The therapy will be provided by the NeuroPoint device using the same protocol
as that used in active treatment arms of NPT-201. The study's primary outcome measure will
be the patient's change from baseline in self-reported 24-hour average pain intensity. The
study will provide active treatment to those participants who received sham therapy in
NPT-201, and will test whether or not additional therapy applications might further improve
pain in those participants who previously received active therapy, but did not achieve
adequate pain relief.
cortical electrostimulation therapy only to those fibromyalgia patients who experienced
inadequate pain reduction in a sham controlled double blinded lead in study, NPT-201
(NCT01825954). The therapy will be provided by the NeuroPoint device using the same protocol
as that used in active treatment arms of NPT-201. The study's primary outcome measure will
be the patient's change from baseline in self-reported 24-hour average pain intensity. The
study will provide active treatment to those participants who received sham therapy in
NPT-201, and will test whether or not additional therapy applications might further improve
pain in those participants who previously received active therapy, but did not achieve
adequate pain relief.
Inclusion Criteria:
- Patient must have successfully completed study NPT-201 and had an inadequate pain
response, defined as <50% reduction in pain from baseline during participation in
NPT-201.
- Patient must provide written informed consent and privacy authorization prior to
participation in the study.
- Female patients of childbearing potential must be willing to use an acceptable method
of birth control for the duration of their study participation. Acceptable birth
control includes a vasectomized partner, contraceptives (oral, parenteral, or
transdermal), intrauterine device, or double barrier method including condoms,
sponge, diaphragm, or vaginal ring with spermicidal jellies or cream. Patients
considered not of childbearing potential must be surgically sterile (total
hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation) or greater than one
year post-menopausal, defined as a complete cessation of menstruation for at least
one year.
- Patients must be willing to refrain from all excluded therapies for the duration of
the study.
- In the opinion of the Investigator, the patient is willing and able to comply with
all protocol-specified requirements.
Exclusion Criteria:
- Patient has a current significant psychological or psychiatric disorder (e.g.,
severe, unstable or poorly controlled depression, severe anxiety or
obsessive-compulsive disorder.
- Patient has a score of 2 or 3 on item 9 of the BDI, or, based on the investigator's
judgment, the patient is at risk of suicidal ideation or behavior.
- Patient has resumed treatment with duloxetine, milnacipran, pregabalin, gabapentin,
sodium oxybate or prohibited narcotics.
- Female patient who is pregnant, planning a pregnancy, or breastfeeding.
- Any anticipated need for surgery that might confound results or interfere with
patient's ability to comply with the protocol.
- The occurrence of a major protocol violation during the lead-in study indicating a
lack of compliance or other significant concern that precludes the patient's ongoing
participation.
We found this trial at
1
site
St. Joseph Mercy Oakland St. Joseph Mercy Oakland (SJMO) is a 443-bed comprehensive, community and...
Click here to add this to my saved trials
